Last updated: 17 November 2023 at 5:15pm EST

Group L Pcolumn Group Gp, L... Net Worth




The estimated Net Worth of Group L Pcolumn Group Gp, L... is at least $1.46 Million dollars as of 15 November 2023. Group L owns over 22,631 units of Ngm Biopharmaceuticals Inc stock worth over $1,462,787 and over the last 2 years Group sold NGM stock worth over $0.

Group L NGM stock SEC Form 4 insiders trading

Group has made over 11 trades of the Ngm Biopharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Group bought 22,631 units of NGM stock worth $15,615 on 15 November 2023.

The largest trade Group's ever made was buying 309,070 units of Ngm Biopharmaceuticals Inc stock on 10 January 2023 worth over $1,480,445. On average, Group trades about 86,351 units every 35 days since 2022. As of 15 November 2023 Group still owns at least 949,862 units of Ngm Biopharmaceuticals Inc stock.

You can see the complete history of Group L stock trades at the bottom of the page.



Insiders trading at Ngm Biopharmaceuticals Inc

Over the last 5 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.



What does Ngm Biopharmaceuticals Inc do?

ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work



What does Ngm Biopharmaceuticals Inc's logo look like?

Ngm Biopharmaceuticals Inc logo

Complete history of Group L stock trades at Ngm Biopharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
15 Nov 2023 Group L Pcolumn Group Gp, L...
Buy 22,631 $0.69 $15,615
15 Nov 2023
949,862
30 Jan 2023 Group L Pcolumn Group Gp, L...
Buy 184,272 $5.00 $921,360
30 Jan 2023
927,231
23 Jan 2023 Group L Pcolumn Group Gp, L...
Buy 9,900 $5.00 $49,500
23 Jan 2023
742,959
19 Jan 2023 Group L Pcolumn Group Gp, L...
Buy 38,139 $5.00 $190,695
19 Jan 2023
733,059
12 Jan 2023 Group L Pcolumn Group Gp, L...
Buy 5,378 $4.95 $26,621
12 Jan 2023
694,920
10 Jan 2023 Group L Pcolumn Group Gp, L...
Buy 309,070 $4.79 $1,480,445
10 Jan 2023
689,542
12 Dec 2022 Group L Pcolumn Group Gp, L...
Buy 300 $4.98 $1,494
12 Dec 2022
380,472
21 Nov 2022 Group L Pcolumn Group Gp, L...
Buy 40,327 $5.00 $201,635
21 Nov 2022
380,172
3 Nov 2022 Group L Pcolumn Group Gp, L...
Buy 139,148 $4.92 $684,608
3 Nov 2022
339,845
27 Oct 2022 Group L Pcolumn Group Gp, L...
Buy 76,877 $4.86 $373,622
27 Oct 2022
200,697
25 Oct 2022 Group L Pcolumn Group Gp, L...
Buy 123,820 $4.81 $595,574
25 Oct 2022
123,820


Ngm Biopharmaceuticals Inc executives and stock owners

Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: